Both in Pharmaceuticals
Entrada Therapeutics vs Upstream Bio
Over the past year TRDA returned −30.4% and UPB returned −86.5%; their daily moves had a correlation of 0.16.
TRDA −30.4% UPB −86.5%Growth of $1, one year, split-adjusted
| Metric | TRDA | UPB |
|---|---|---|
| Price | $4.72 | $3.39 |
| Market cap | $183.8M | $185.7M |
| Today | −7.63% | +1.19% |
| 1 month | −13.9% | −30.1% |
| 6 months | −70.0% | −62.8% |
| Year to date | −54.1% | −87.5% |
| 1 year | −32.1% | −86.9% |
| Revenue growth (YoY) | −53.9% | −17.5% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −4762.0% | −5136.1% |
| P/E (TTM) | — | — |
| Price / sales | 39.2× | 58.8× |
| Net cash | $223.0M | $261.3M |
| Dividend yield | — | — |
| Volatility (60d) | 84.9% | 82.1% |
| Short % of float | 13.0% | 13.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).